NL-OMON43117撤回2 期
Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculosis after successful intensive-phase treatment. - Safety of RUTI® vaccine in MDR-TB
Archivel Farma S.L.0 个研究点目标入组 5 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Female or Male patients (aged * 18);- Females of childbearing potential must have a negative pregnancy test at enrolment and must agree to use highly effective methods of birth control during and 30 days after the study;- The patient must provide written informed consent;- The patient must be willing and able to attend all study visits and comply with all study procedures;- diagnosed with active MDR-TB and therefore treated with second-line TB drugs;- MDR-TB patients with Mycobacterium tuberculosis (or Mycobacterium africanum) confirmed by sputum culture;- having successfully completed 16 (Cohort A) or 12 weeks (Cohort B) of MDR-TB treatment, fully supervised, with beneficial initial response to therapy, evidenced by:;1) Clinical response criteria: in patients initially presenting with three classical symptoms (weight loss, chronic cough, fever or night sweats), clinical improvement should be recorded in at least two of three symptoms at least 4 weeks apart; ;in patients with only two of these symptoms present initially, patients should show improvement in at least one symptom, at least 4 weeks apart; and in addition, patients should not develop clinical deterioration * i.e., on-going weight loss, or increased cough, or new-onset fever or night sweats. ;In addition, the attending physician should ascertain an overall clinical beneficial response to treatment. Transient deterioration of chest radiographic abnormalities might be explained by a paradoxical inflammatory response, and this may therefore not necessarily be interpreted as treatment failure; such decision depends on consensus with the DSMB. ;2) Microbiological response criteria: as evidenced by improvement in at least 2 measurements at least 4 weeks apart, using MGIT (liquid culture microbiological assay read at 10 days)
排除标准
- •- Inability to provide written informed consent ;- Women reported, or detected, or willing to be pregnant during the trial period;;- Severity of illness precluding full evaluation: expected early death, evidenced by respiratory failure, low blood pressure, WHO performance score 3-4; Central Nervous System involvement of TB (TB meningitis, intra-cranial tuberculomas) as there is too little evidence for effective drug penetration for second-line TB drugs;;- Major co-morbid conditions precluding full evaluation, i.e., active lung cancer, acute coronary syndrome, heart failure exceeding NYHA class 2; a diagnosis of metastasized malignancy; renal failure in excess of creatinine clearance < 30 ml / min calculated by the Cockcroft-Gault formula, which would severely complicate administration of aminoglycosides and capreomycin, considered as the major second-line TB drugs; obesity (BMI>30 kg/m2); chronic liver disease * Child-Pugh class C; ;- Receiving or anticipated to receive a daily dose of * 10 mg of systemic prednisone or equivalent within the period starting 14 days prior to enrolment. Note: patients are allowed to receive an acute, short course of methylprednisolone or prednisone or equivalent for management of an acute exacerbation of COPD or reactive airway disease in asthmatics ;- Cytotoxic chemotherapy or radiation therapy within the previous 3 months;- HIV co-infection, if CD4 count <350 copies/mL; those with 350 copies/mL are expected to be able to mount a sufficient cellular immune response and will therefore be eligible;- Blood transfusion in the last three weeks prior to the trial;- Documented allergy to TB vaccines, notably, to the RUTI® vaccine.;-Any of the following laboratory parameters:
- •* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x upper limit of normal (ULN)
- •* total bilirubine > 2 x ULN
- •* Neutrophil count * 500 neutrophils / mm3
- •* Platelet count < 50.000 cells / mm3
研究者
相似试验
进行中（未招募）
1 期
V160 2-Dose and 3-Dose Regimens vs. Placebo in Healthy CMV Seronegative FemalesCytomegalovirus infection (CMVi)MedDRA version: 20.0Level: LLTClassification code 10009703Term: CMV infectionSystem Organ Class: 100000004862EUCTR2017-004233-86-FIMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,100
进行中（未招募）
1 期
Evaluation of the safety and ability to induce an immune response of RUTI vaccine for patients that have completed the first 12 or 16 weeks of standard therapy for drug-resistant tuberculosisThe medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and IsoniazidEUCTR2016-000850-36-NLArchivel Farma S.L.27
进行中（未招募）
1 期
Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue VaccineDengueMedDRA version: 20.0Level: LLTClassification code 10012309Term: DengueSystem Organ Class: 10021881 - Infections and infestationsEUCTR2022-003868-25-Outside-EU/EEAInstituto Butantan
进行中（未招募）
1 期
V160 2-Dose and 3-Dose Regimens vs. Placebo in Healthy CMV Seronegative FemalesEUCTR2017-004233-86-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.2,100
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Stage III or IV Malignant MelanomaRevised Protocol 03 Incorporating Amendment 02, 03 and 05 (version 1.0, dated 12-Mar-07)+ Pharmacogenetics Blood Sample Amendment 01 - Site Specific (version 1.0 dated 01-Aug-05)MELANOMAEUCTR2005-002678-31-GBBristol-Myers Squibb International Corporation100